Results 101 to 110 of about 104,861 (298)

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
A Quintas-Cardama, A Quintas-Cardama, A Quintas-Cardama, AJ Tipping, AJ Tipping, B Zhang, C Akgul, C Bellodi, G Gurel, H de Lavallade, H Konig, HG Jorgensen, HM Kantarjian, J Kuroda, KJ Aichberger, L Legros, M Copland, M Copland, NB Heaney, R Chen, R Tang, RG Powell, RM Stone, S Chu, SM Graham, SV Sharma, T Kobayashi, Y Chen   +27 more
core   +1 more source

Colon-Targeted Poly(ADP-ribose) Polymerase Inhibitors Synergize Therapeutic Effects of Mesalazine Against Rat Colitis Induced by 2,4-Dinitrobenzenesulfonic Acid

Pharmaceutics
Background/Objectives: In addition to oncological applications, poly(ADP-ribose) polymerase (PARP) inhibitors have potential as anti-inflammatory agents.
Changyu Kang, Jaejeong Kim, Yeonhee Jeong, Jin-Wook Yoo, Yunjin Jung   +4 more
doaj   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Abdel-Fatah, TMA, Agarwal, D, Albarakati, N, Alsubhi, N, Arora, A, Ball, G, Caldas, C, Chan, S, Doherty, R, Ellis, IO, Green, A, Madhusudan, S, Moseley, P, Perry, C, Rakha, EA, Russell, R, Seedhouse, C   +16 more
core   +1 more source

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review

Diagnostics, 2019
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of advanced
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis   +6 more
doaj   +1 more source

N4‐acetylcytidine in LncRNA Gm26917 Promotes Translation in Female Germline Stem Cells by Recruiting Ribosomal Protein mRNA via EEF1A1

Advanced Science, EarlyView.
This work establishes that ac4C modification on lncRNA Gm26917 governs its spatial interactions with Rpl10 mRNA, and RBP EEF1A1 mediates the interaction between Gm26917 and Rpl10. It elucidates a novel ac4C‐Gm26917‐EEF1A1‐Rpl10 axis in FGSC maintenance both in vitro and in vivo, and provides a potential molecular target for modulating germ cell ...
Xinyue Li, Xiaopeng Hu, Ji Wu
wiley   +1 more source

In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. [PDF]

, 2016
Aberrant Hedgehog (Hh)/glioma-associated oncogene (GLI) signaling has been implicated in cancer progression. Here, we analyzed GLI1, Sonic Hedgehog (Shh) and NF-κB expression in 51 breast cancer (ductal carcinoma) tissues using immunohistochemistry ...
Bei, R., Benvenuto, M, Bonanno, E, Cucchi, Danilo, DE SMAELE, Enrico, DI STEFANO, Enrica, Fantini, M, Frajese, Gv, Gulino, Alberto, Masuelli, Laura, Mattera, Rosanna, Modesti, A, Orlandi, A, Screpanti, Isabella   +13 more
core   +1 more source

Advances in the use of PARP inhibitor therapy for breast cancer

Drugs in Context, 2018
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj   +1 more source

PARP Inhibitors for Cancer Therapy

Cell, 2017
Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations.
Ken Y, Lin, W Lee, Kraus
openaire   +2 more sources

NUDT21 Drives T‐Cell Acute Lymphoblastic Leukemia Through Dual Regulation of Alternative Polyadenylation and Transcriptional Activation

Advanced Science, EarlyView.
In summary, our study defines a coordinated oncogenic model in which NUDT21 integrates alternative polyadenylation–dependent UBE2D3 stabilization and transcriptional activation to sustain MYC‐driven T‐ALL cell survival, thereby establishing NUDT21 as a central regulatory node and a promising therapeutic target.
Conglian Qiu, Jianwei Wang, Zhiheng Li, Qi Ji, Hui Zhang, Qinyi Zhang, Senlin Zhang, Juanjuan Yu, Yanfang Tao, Yijun Wu, Chunxia Shi, Zong Zai, Zimu Zhang, Yizhen Li, Zhenjiang Bai, Shaoyan Hu, Jian Pan, Yang Yang, Shuiyan Wu   +18 more
wiley   +1 more source